How new US tariffs impact India's trade and pharma sector

The United States has imposed fresh tariffs on several Indian exports, including a forced labour provision that targets goods linked to alleged coercive practices, and is advancing a plan to levy tariffs on imported drugs. These measures directly threaten India's competitive edge in global markets and put pressure on its pharmaceutical industry, a key exporter to the US. The forced labour tariffs apply to products such as textiles and agricultural items, while the drug tariff plan could raise costs for Indian generic medicine makers who supply nearly half of US prescriptions. The Indian government has responded by initiating trade talks with US officials, seeking exemptions or delays, particularly for the pharma sector. Industry bodies warn that without a negotiated solution, Indian exporters could lose market share to competitors like Vietnam and Bangladesh. The drug tariff, if enacted, would also increase healthcare costs for American patients. Meanwhile, the forced labour provision requires Indian firms to prove supply chain compliance, a process that may be costly and time-consuming. The outcome of ongoing negotiations remains uncertain, but both sides have expressed willingness to find a middle ground.